Cancer Management and Research (Dec 2020)
The Detection of Plasma Soluble Podoplanin of Patients with Breast Cancer and Its Clinical Signification
Abstract
Xinyi Zhu,1,2,* Mengqiao Xu,3,* Xingpeng Zhao,4,* Fei Shen,1,2 Changgeng Ruan,1,2 Yiming Zhao1,2 1Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou 215006, Jiangsu, People’s Republic of China; 2Collaborative Innovation Center of Hematology, Soochow University, Suzhou 215006, Jiangsu, People’s Republic of China; 3Department of Laboratory Medicine, The Affiliated Municipal Hospital of Taizhou University, Taizhou 318000, Zhejiang, People’s Republic of China; 4Clinical Laboratory Center, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471000, Henan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yiming ZhaoJiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of the Ministry of Health, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, Jiangsu, People’s Republic of ChinaTel + 86-512-67781379Fax + 86-512-65113556Email [email protected]: Podoplanin (PDPN) is a type-1 membrane sialoglycoprotein that is expressed in many cancer tumors including breast cancer; nonetheless, its roles in tumor occurrence, development, and metastasis are unclear. In this study, we aimed to investigate the clinical significance of plasma soluble PDPN (sPDPN) levels in patients with breast cancer and its significance in the diagnosis and metastasis.Materials and Methods: Blood samples from healthy controls (CTL), patients with fibroadenomas of breast (FOB), and breast cancer (pathological type: invasive ductal carcinoma, IDC) were collected. sPDPN levels in the plasma of CTL and patients with FOB and IDC were measured by the ELISA.Results: The plasma sPDPN levels in IDC patients (159 cases, 22.59± 3.70 ng/mL) were higher than those in FOB patients (50 cases, 8.29± 1.09 ng/mL; P< 0.05) and CTL (100 cases, 1.21± 0.12 ng/mL; P< 0.0001). The sPDPN levels in patients at stage III and stage IV (30.08± 4.66 ng/mL) were higher than in patients at stage I and stage II (11.84± 1.12 ng/mL; P=0.005). The sPDPN levels in patients with high-moderate and moderate differentiation (17.50± 3.02 ng/mL) were lower than those in patients with moderately low and low differentiation (35.73± 4.26 ng/mL; P=0.026). The sPDPN levels in patients with metastasis (30.60± 4.27 ng/mL) were much higher than those in patients without metastasis (13.02± 1.30 ng/mL; P=0.017).Conclusion: Plasma sPDPN may be used as a new marker for the determination of the clinical stage, differentiation degree, and metastasis status of breast cancer.Keywords: podoplanin, breast cancer, ELISA, monoclonal antibody
